Public Release: 

Microbeads to combat infection show promise in burn wound simulations

A potential alternative to antibiotics, protein-coated beads block bacteria from binding host cells

PLOS

IMAGE

IMAGE: Diagrams showing the burn wound geometry (left) and a cartoon representation of the mathematical model (right). Host cells are covered by a liquid layer known as the exudate, which is... view more 

Credit: Image created by Dr. Paul A. Roberts.

Computer simulations of microscopic, protein-coated beads that block bacteria from binding to host cells suggest that the microbeads could help reduce or eliminate bacterial infections in burn wounds. Paul Roberts of the University of Birmingham, U.K., and colleagues present these new findings, funded by the BBSRC, in PLOS Computational Biology.

The microbeads were developed several years ago as a potential alternative to antibiotics, which are difficult to innovate quickly enough to keep up with the rapid emergence of bacterial strains that are resistant to existing drugs. The tiny plastic spheres are coated with the same protein used by many bacteria to bind host cells. Thus, they compete with bacteria for binding sites, physically keeping them from attaching to host cells.

Previous laboratory research has demonstrated the potential of the microbeads to treat infections in burn wounds in rats. To further explore this potential, Roberts and colleagues developed a mathematical model that simulates microbead treatment of rats with burn wounds infected by Pseudomonas aeruginosa, a bacterium that often infects burn wounds in humans.

The researchers ran computer simulations for a range of parameter values representing different infection scenarios and microbead treatment strategies. This enabled them to explore which conditions allow for effective microbead treatment and how to refine microbead treatment to maximize its anti-bacterial power.

The simulations showed that microbead treatment is unlikely to be effective on its own, but when combined with a technique called debridement, it could significantly reduce or eliminate infection. Debridement is a method of cleansing a burn wound with a cloth and is already used regularly to treat burn wounds in humans.

"Our results also suggest that these microbeads could be used to complement traditional antibiotic drugs," Roberts says. "In theory, this would allow us to eliminate bacterial infections more rapidly, reducing the quantity of antibiotics used and hence lessening the chances that bacteria will develop resistance to them."

Next, the model results will be tested in laboratory experiments to determine if a combined microbead-debridement treatment is as effective as predicted. Meanwhile, Roberts and colleagues are developing more sophisticated mathematical models in order to explore the best ways to combine microbeads and debridement with traditional antibiotic treatment.

###

In your coverage please use this URL to provide access to the freely available article in PLOS Computational Biology: http://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1006071

Citation: Roberts PA, Huebinger RM, Keen E, Krachler A-M, Jabbari S (2018) Predictive modelling of a novel anti-adhesion therapy to combat bacterial colonisation of burn wounds. PLoS Comput Biol 14(5): e1006071. https://doi.org/10.1371/journal.pcbi.1006071

Funding:

PAR, EK, AMK and SJ gratefully acknowledge support from the Biotechnology and Biological Sciences Research Council (grant code: BB/M021386/1, http://www.bbsrc.ac.uk/). PAR and SJ would also like to thank the Wellcome Trust (grant code: 1516ISSFFEL9, http://www.wellcome.ac.uk/) for funding a parameterisation workshop at the University of Birmingham (UK). RMH acknowledges support from the Golden Charity Guild Charles R. Baxter, MD Chair in Burn Surgery (http://www.utsouthwestern.edu), which provided research funding. AMK thanks the UT System for support through a University of Texas System Science and Technology Acquisition and Retention (STARs) Program award (https://www.utsystem.edu/offices/health-affairs/stars-program). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: AMK is a co-inventor on the patent `Modulating bacterial MAM polypeptides in pathogenic disease' (US9529005, issued Dec 27, 2016).

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.